Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.27 -1.03 (-0.99%)
Streaming Delayed Price Updated: 11:48 AM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
What 7 Analyst Ratings Have To Say About Merck & Co
Via Benzinga
Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market
The company inked a new deal on Monday to test a new regimen using a second cancer vaccine. 
Via Investor's Business Daily
Moderna Teams Up With Chinese Biotech To Assess Cell-Based Therapy And Cancer Vaccine Combo
A Chinese biotech, CARsgen Therapeutics and Moderna Inc (NASDAQ: MRNA) have collaborated 
Via Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023
These are the pharma stocks to buy at undervalued levels as they represent companies investing heavily in research and development. 
Via InvestorPlace
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a... 
Via Talk Markets
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Check Out What Whales Are Doing With MRK
Via Benzinga
Is Merck Stock a Buy Now?
There's a lot to like about this blue-chip company, but it has its problems, too. 
Via The Motley Fool
Merck & Co Unusual Options Activity
Via Benzinga
Merck Reveals Mixed Results From Pivotal Kidney Cancer Study Of Welireg In Pretreated Patients
Merck & Co Inc (NYSE: MRK) released topline results from LITESPARK-005, a Phase 3 trial investigating WELIREG (belzutifan), Merck's oral hypoxia-inducible  
Via Benzinga
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Federal Court Rules To Prohibit Access To Abortion Pill: Supreme Court To Weigh In
The 5th Circuit Court of Appeals ruled Wednesday to prohibit access to mifepristone, the drug known as the abortion pill, in a case filed against the Food and Drug Administration. 
Via Benzinga
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Peering Into Merck & Co's Recent Short Interest
Via Benzinga
Expert Ratings for Merck & Co
Via Benzinga
The 3 Most Undervalued Penny Stocks to Buy Now: August 2023
These undervalued penny stocks each provide big upside potential, while trading with relatively high margins of safety. 
Via InvestorPlace
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare
Healthcare stocks are starting to shine in 2023 after bottoming out and MRK stock is particularly appealing. Here's why. 
Via InvestorPlace
Pharma ETFs in Focus Post Q2 Earnings
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
The 3 Best ESG Stocks to Buy in August
Although doing right would seem to come at a cost to shareholder profit potential, these best ESG stocks to buy prove otherwise. 
Via InvestorPlace
My Oh My, Merck Stock Is a No-Brainer Income Stock to Buy
The pharmaceutical company has outperformed the market over the past five years. 
Via The Motley Fool
The 3 Best Healthcare Stocks to Buy in August
Healthcare is always the answer in the face of volatility. Here are the three best healthcare stocks to buy in the sector. 
Via InvestorPlace
Mirati Rockets 26% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit
The company announced updates in cancer, a quarterly beat, a $300 million deal and its CEO departure. 
Via Investor's Business Daily
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventing the disease. However, recent research on the... 
Via Benzinga
Merck Is Driving Ginkgo Bioworks Stock Higher Monday: What's Going On?
Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher Monday after the company announced a collaboration with Merck & Company Inc (NYSE: MRK) focused on 
Via Benzinga
Merck, Delta Air Lines And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower on Thursday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential
Via Investor Brand Network
Exposures Product Safety
Is It Time to Buy the Dow Jones' 3 Worst-Performing July Stocks?
These three Dow stocks had a tough go of it in July; is the pain over, or are investors in for more hurt in the months ahead? 
Via The Motley Fool
Rising Dividend Make Zoetis a Doggone Winner
Investors that typically focus on other large cap pharmaceutical plays may wish to consider an alternative bet on pets with shares of Zoetis. 
Via MarketBeat
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.